Huge anti-cancer potential for Oxford Biomedica
Article Abstract:
Oxford Biomedica has seen a drop in its stock price since the company's stock flotation in 1996. The company could achieve large rewards if it can gain a stake in the global gene therapy market, estimated to grow to $10 billion in the decade from 1998. The company is specialising in cancer research and aims to develop a switch for anti-tumor genes to stimulate the production of proteins that kill cancer cells after a tumor has been located. Clinical trials are starting in late 1998, and the company has a research agreement with Rhone-Poulenc Rorer. Oxford Biomedica forecasts a loss of 3.7 million pounds sterling for 1998.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Oxford Biomedica
Article Abstract:
Oxford Biomedica is in a strong position with its therapeutics business based on genetic research. The company has set up a drug discovery unit, and its technology for isolating genes associated with specific ailments is being used by AstraZeneca. Other major pharmaceutical partners look set to follow. the company is likely to report a loss of some 4 million pounds sterling for 1999. Oxford may join TechMARK, once it has two products going through clinical trials, which should occur by 4th qtr 2000.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
An active interest
Article Abstract:
Huntingdon Life Sciences was enjoying a rise in its stock price until 1997, when a TV documentary showed employees treating animals unkindly. The company lost contracts, and its stock price fell, with major stockholders selling stakes.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Fighting for pension cash. Minimum interest
- Abstracts: Are Canadians rich or poor? Blame monetary policies. Tax can't be neutral
- Abstracts: Structural genomics and its importance for gene function analysis. The hair follicle as a gene therapy target
- Abstracts: Funds and finance: duty bound. Stamp out stamp duty. Why investors should mind the US gap: The fate of equities this year will depend in large part on investors' willingness to finance the huge deficit in US balance of payments
- Abstracts: Body maintenance for profit. Fit for profit? Fitness First: fit for the market